Comparative Assessment of Skin and Subcutaneous Toxicity in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX

  • Published : 2013.03.30


Objective: The study was designed to assess the skin and subcutaneous toxicity in patients with advanced colorectal carcinoma treated with four different schedules of FOLFOX. Methods: The patients with histologically confirmed advanced colorectal carcinoma (CRC) were included in the study as per specified inclusion criteria. Toxicity was graded according to CTC v2.0. The frequency of grade 3 and 4 adverse effects were comparatively assessed in each treatment arm. Results: Very severe toxicity was attributed to the FOLFOX7 schedule. The difference between the incidence rate of grade 4 toxicity with all other grades for all parameters of skin and subcutaneous toxicity was highly significant (p=0.00<0.001). Grade 4 hand and foot syndrome was reported only in the FOLFOX7 treatment arm. The most frequent adverse symptom of skin and subcutaneous toxicity reported in the patients treated with modified schedule of FOLFOX was pruritus (grade 1). Frequency and onset of skin and subcutaneous toxic symptoms like alopecia (p=0.000), nail discoloration (p=0.021) and pruritis (p=0.000) was significantly different in each FOLFOX treatment arm. A few cases of oncholysis were also reported in the FOLFOX7 treatment arm. Hand and foot syndrome was fast progressing in patients with grade 1 toxicity. Conclusion: Higher frequency and severity of hand and foot syndrome and pruritus wasa found in the FOLFOX7 treatment arm. Skin and subcutaneous toxicity was comparatively low in the FOLFOX6 treatment arm.


  1. Asgari MM, Haggerty JG, McNiff JM, Milstone LM, Schwartz PM (1999). Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol, 26, 287-94.
  2. Baack BR, Burgdorf WH (1991). Chemotherapy-induced acral erythema. J Am Acad Dermatol, 24, 457-61
  3. Bano N, Najam R, Mateen A, Qazi F (2012a). High and low dose folinic acid, 5-fluorouracil bolus and continuous infusion for poor-prognosis patients with advanced colorectal carcinoma. Asian Pac J Cancer Prev, 13, 3589-93.
  4. Bano N, Najam R, Mateen A, Qazi F (2012b). Implication of age and gender on cardio toxicity in patients treated with two schedules of 5FU/LV. Pak J Pharmacol, 29, 43-51.
  5. Bano N, Najam R (2013a). Oxaliplatin: a review of its use in advanced colorectal carcinoma. Int J Pharm Sci Rev Res, 18, 133-7.
  6. Bano N, Najam R, Mirza T, Hassan S (2013b). Review of colorectal carcinoma and specific disease features in the population of Pakistan. Asian J Pharm Clin Res, 6, 13-17.
  7. Bano N, Najam R, Qazi F (2013c). Adverse cardiac manifestations of cisplatin - a review. Int J Pharm Sci Rev Res, 18, 80-5.
  8. Bellmunt J, Navarro M, Hidalgo R, Sole LA (1988). Palmarplantar erythrodysesthesia syndrome associated with shortterm continuous infusion (5 days) of 5-fluorouracil. Tumori, 74, 329-31.
  9. Cheng LC, Chen HH, Lin SE (2008). Hypersensitivity reactions to oxaliplatin: a prospectively collected study of 25 cases treated in one institute. J Soc Colon Rectal Surgeon, 19, 115-22.
  10. Chin SF, Tchen N, Oza AM, et al (2001). Use of "bag balm" as topical treatment of palmarplantar erythrodysesthesia syndrome in patients receiving selected chemotherapeutic agents. Proceedings of the ASCO, 20 (abstract 1632).
  11. Duffour J, Thézenas S, Dereure O, et al (2010). Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: A pilot comparative study. Eur J Cancer, 46, 3169-74.
  12. Damaske A, Ma N, Williams R (2012). Leucovorin-induced hypersensitivity reaction. J Oncol Pharm Pract, 18, 136-9.
  13. Eng C (2009). Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol, 6, 207-18.
  14. Fabian CJ, Molina R, Slavik M, et al (1990). Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs, 8, 57-63.
  15. Gerbrecht BM (2003). Current Canadian experience with capecitabine. Cancer Nurs, 26, 161-7.
  16. Ichikawa Y, Goto A, Hirokawa S, et al (2009). Allergic reactions to oxaliplatin in a single Institute in Japan. Jpn J Clin Oncol, 39, 616-20
  17. Jucgla A, Sais G (1997). Diagnosis in oncology: HFS. J Clin Oncol, 15, 3164.
  18. Kim YH, Muro K, Yasui H, et al (2012). A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol, 70, 583-90.
  19. Komamura H, Higashiyama M, Hashimoto K, et al (1995). Three cases of chemotherapy-induced acral erythema. J Dermatol, 22, 116-21.
  20. Lee KH, Chang HJ, Han SW, et al (2013). Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol [Epub ahead of print].
  21. Lassere Y, Hoff P (2004). Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs, 8, 31-40.
  22. Leo S, Tatulli C, Taveri R, et al (1994). Dermatological toxicity from chemotherapy containing 5-fluorouracil. J Chemother, 6, 423-6.
  23. Lopez AM, Wallace L, Dorr RT, et al (1999). Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol, 44, 303-6.
  24. Lauman MK, Mortimer J (2001). Effect of pyridoxine on the incidence of palmar plantar erythroderma in patients receiving capecitabine. Proceedings of the ASCO, 20, 1565.
  25. Mrozek-Orlowski ME, Frye DK, Sanborn HM (1999). Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum, 26, 753-62.
  26. Markman M, Kennedy A, Webster K, et al (1999). Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol, 17, 1141-5.
  27. Najam R, Bano N, Mateen A (2012). Drug Induced Thrombocytopenia in Patients of Advanced Colorectal Carcinoma Treated with 5FU/LV and FOLFOX 4. IJAPR, 3, 1269-75.
  28. Polyzos A, Tsavaris N, Kosmas C, et al (2001). Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology, 61,129-33.
  29. Shlebak AA, Clark PI, Green JA (1995). Hypersensitivity and cross reactivity to cisplatin and analogues. Cancer Chemother Pharmacol, 35, 349-51.
  30. Schüll B, Kornek GV, Scheithauer W (2001). Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule. Ann Oncol, 12, 1653-4.
  31. Thomas RR, Quinn MG, Schuler B, Grem JL (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 97, 2301-7.
  32. Vakalis D, Loannides D, Lazaridou E, Mattheou-Vakali G,Teknetzis A (1998). Acral erythema induced by chemotherapy with cisplatin. Br J Dermatol, 139, 750-1.
  33. Van Cutsem E, Findlay M, Osterwalder B, et al (2000). Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol, 18, 1337-45.
  34. Wehler TC, Cao Y, Galle PR, et al (2012). Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. Oncology Letters, 3, 1191.
  35. Wyatt AJ, Leonard GD, Sachs DL (2006), Cutaneous reactions to chemotherapy and their management. Am J Clin Dermat, 7, 45-63.
  36. Yanai T, Iwasa S, Hashimoto H et al. (2012). Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer. Anticancer Res, 32, 5521-6.
  37. Yoshida Y, Hoshino S, Aisu N, et al (2013). Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01). World J Surg Oncol, 11, 1-5.
  38. Zhang C, Wang J, Gu H, et al (2012). Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials. Oncology Letters, 3, 831.